{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:36:51Z","timestamp":1792136211695,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100032501","name":"CureVac","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032501","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adoptive T cell therapy (ACT) has shown remarkable clinical success in treating haematological malignancies; however, its efficacy against solid tumours remains limited. This is largely due to poor persistence and functionality of transferred T cells, restricted tumour infiltration, and the presence of an immunosuppressive tumour microenvironment. Here, using the MC38-OVA murine tumour model, we tested whether combining Transgenic T cell receptor (TCR\n                    <jats:sup>tg<\/jats:sup>\n                    ) T cell therapy with an adjunctive mRNA-based immunotherapy could address these challenges and drive effective and long-lasting anti-tumour response. Tumour-bearing mice were treated with different numbers of in vivo-activated, ovalbumin (OVA)-specific TCR\n                    <jats:sup>tg<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells harvested from OT-I mice, either alone or in combination with lipid nanoparticle (LNP)-encapsulated mRNA encoding OVA. Tumour progression was monitored, and analyses were performed to assess survival, T cell expansion, phenotype, infiltration, and effector function. The combination therapy of a low dose of TCR\n                    <jats:sup>tg<\/jats:sup>\n                    T cells and mRNA immunotherapy led to robust and durable anti-tumour responses, significantly improving survival compared to monotherapies. Notably, transferred TCR\n                    <jats:sup>tg<\/jats:sup>\n                    T cells expanded only following mRNA immunotherapy, and circulating TCR\n                    <jats:sup>tg<\/jats:sup>\n                    \u00a0T cells exhibited a memory precursor and effector memory phenotype. These cells infiltrated tumours effectively and displayed more potent cytotoxic activity, resulting in regression of large tumours\u2014even without prior lymphodepletion. Overall, our findings demonstrate that mRNA immunotherapy can substantially enhance the efficacy of TCR\n                    <jats:sup>tg<\/jats:sup>\n                    T cell therapy in a solid tumour model. This combinatorial approach holds promise for overcoming key limitations of ACT by boosting T cell expansion, persistence, infiltration, and functional capacity within the tumour microenvironment.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-65120-4","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:45:39Z","timestamp":1786160739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["mRNA-based immunotherapy improves the efficacy of adoptively transferred TCR transgenic T cells in a murine solid tumour model"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8477-3558","authenticated-orcid":false,"given":"Janna","family":"Krueger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5312-5486","authenticated-orcid":false,"given":"Janne J.","family":"Ruotsalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-0023","authenticated-orcid":false,"given":"Johannes","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-9412","authenticated-orcid":false,"given":"Regina","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"65120_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002723","author":"K Kirtane","year":"2021","unstructured":"Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: Review of the literature and challenges ahead. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-002723 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"65120_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040835","author":"MY Want","year":"2023","unstructured":"Want, M. Y., Bashir, Z. & Najar, R. A. T cell based immunotherapy for cancer: Approaches and strategies. Vaccines https:\/\/doi.org\/10.3390\/vaccines11040835 (2023).","journal-title":"Vaccines"},{"key":"65120_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n, V. et al. Adoptive T cell therapy for solid tumors: Current landscape and future challenges. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1352805 (2024).","journal-title":"Front. Immunol."},{"key":"65120_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267\u2013276. https:\/\/doi.org\/10.1038\/nrclinonc.2013.46 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65120_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"A-M Tsimberidou","year":"2021","unstructured":"Tsimberidou, A.-M. et al. T-cell receptor-based therapy: An innovative therapeutic approach for solid tumors. J. Hematol. Oncol. 14, 102. https:\/\/doi.org\/10.1186\/s13045-021-01115-0 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"65120_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","author":"J Chesney","year":"2022","unstructured":"Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-005755 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"65120_CR7","doi-asserted-by":"publisher","DOI":"10.12659\/msm.948125","volume":"31","author":"DV Parums","year":"2025","unstructured":"Parums, D. V. A review of CAR T cells and adoptive T-cell therapies in lymphoid and solid organ malignancies. Med. Sci. Monit. 31, e948125. https:\/\/doi.org\/10.12659\/msm.948125 (2025).","journal-title":"Med. Sci. Monit."},{"key":"65120_CR8","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke, M. et al. Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: A phase 1 trial. Nat. Med. 31, 2365\u20132374. https:\/\/doi.org\/10.1038\/s41591-025-03650-6 (2025).","journal-title":"Nat. Med."},{"key":"65120_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0603","author":"J Moser","year":"2025","unstructured":"Moser, J. et al. 603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator\u2019s choice in previously treated advanced cutaneous melanoma. J. ImmunoTherapy Cancer https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0603 (2025).","journal-title":"J. ImmunoTherapy Cancer"},{"key":"65120_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003811","author":"M Ishihara","year":"2022","unstructured":"Ishihara, M. et al. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003811 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"65120_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang, P., Zhang, G. & Wan, X. Challenges and new technologies in adoptive cell therapy. J. Hematol. Oncol. 16, 97. https:\/\/doi.org\/10.1186\/s13045-023-01492-8 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"65120_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12901-3","volume":"11","author":"G Parisi","year":"2020","unstructured":"Parisi, G. et al. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat. Commun. 11, 660. https:\/\/doi.org\/10.1038\/s41467-019-12901-3 (2020).","journal-title":"Nat. Commun."},{"key":"65120_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett, B. et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol. 14, 1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935 (2023).","journal-title":"Front. Immunol."},{"key":"65120_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.annonc.2025.04.001","volume":"36","author":"S Mart\u00edn-Lluesma","year":"2025","unstructured":"Mart\u00edn-Lluesma, S. et al. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: A systematic review and meta-analysis. Ann. Oncol. 36, 909\u2013919. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.001 (2025).","journal-title":"Ann. Oncol."},{"key":"65120_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790. https:\/\/doi.org\/10.1038\/s41571-022-00689-z (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65120_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05206-7","volume":"22","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. The potential and promise for clinical application of adoptive T cell therapy in cancer. J. Transl. Med. 22, 413. https:\/\/doi.org\/10.1186\/s12967-024-05206-7 (2024).","journal-title":"J. Transl. Med."},{"key":"65120_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.12.004","author":"YR Li","year":"2025","unstructured":"Li, Y. R., Lyu, Z., Shen, X., Fang, Y. & Yang, L. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol. Sci. https:\/\/doi.org\/10.1016\/j.tips.2024.12.004 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"65120_CR18","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1158\/0008-5472.Can-09-0579","volume":"69","author":"J Kohlmeyer","year":"2009","unstructured":"Kohlmeyer, J. et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 69, 6265\u20136274. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-0579 (2009).","journal-title":"Cancer Res."},{"key":"65120_CR19","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1078-0432.Ccr-13-3017","volume":"20","author":"T Chodon","year":"2014","unstructured":"Chodon, T. et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 20, 2457\u20132465. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-3017 (2014).","journal-title":"Clin. Cancer Res."},{"key":"65120_CR20","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.Ccr-18-3496","volume":"25","author":"TS Nowicki","year":"2019","unstructured":"Nowicki, T. S. et al. A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab. Clin. Cancer Res. 25, 2096\u20132108. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3496 (2019).","journal-title":"Clin. Cancer Res."},{"key":"65120_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002449","author":"C Saberian","year":"2021","unstructured":"Saberian, C. et al. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-002449 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"65120_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453. https:\/\/doi.org\/10.1126\/science.aay5967 (2020).","journal-title":"Science"},{"key":"65120_CR23","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853. https:\/\/doi.org\/10.1038\/s41591-023-02612-0 (2023).","journal-title":"Nat. Med."},{"key":"65120_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0590","author":"JW Smithy","year":"2025","unstructured":"Smithy, J. W. et al. 590 A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME-encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma. J. ImmunoTherapy Cancer https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0590 (2025).","journal-title":"J. ImmunoTherapy Cancer"},{"key":"65120_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081251","volume":"10","author":"N Roth","year":"2022","unstructured":"Roth, N. et al. Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homologous and heterologous neutralising antibody responses. Vaccines 10, 1251 (2022).","journal-title":"Vaccines"},{"key":"65120_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/imr.12135","volume":"257","author":"JG Crompton","year":"2014","unstructured":"Crompton, J. G., Sukumar, M. & Restifo, N. P. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol. Rev. 257, 264\u2013276. https:\/\/doi.org\/10.1111\/imr.12135 (2014).","journal-title":"Immunol. Rev."},{"key":"65120_CR27","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","volume":"107","author":"M Ahmadzadeh","year":"2006","unstructured":"Ahmadzadeh, M. & Rosenberg, S. A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107, 2409\u20132414. https:\/\/doi.org\/10.1182\/blood-2005-06-2399 (2006).","journal-title":"Blood"},{"key":"65120_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/2326-6066.CIR-20-0800","volume":"9","author":"E Hajaj","year":"2021","unstructured":"Hajaj, E. et al. Alternative splicing of the inhibitory immune checkpoint receptor SLAMF6 generates a dominant positive form, boosting T-cell effector functions. Cancer Immunol. Res. 9, 637\u2013650. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0800 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"65120_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50062-y","volume":"14","author":"T Oba","year":"2024","unstructured":"Oba, T., Long, M. D., Ito, K.-i & Ito, F. Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma. Sci. Rep. 14, 2394. https:\/\/doi.org\/10.1038\/s41598-023-50062-y (2024).","journal-title":"Sci. Rep."},{"key":"65120_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.Cd-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero, I., Rouzaut, A., Motz, G. T. & Coukos, G. T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 4, 522\u2013526. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0985 (2014).","journal-title":"Cancer Discov."},{"key":"65120_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao, J. & Yan, Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer 6, 580\u2013592. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.003 (2020).","journal-title":"Trends Cancer"},{"key":"65120_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094934","author":"S Sotirov","year":"2024","unstructured":"Sotirov, S. & Dimitrov, I. Tumor-derived antigenic peptides as potential cancer vaccines. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25094934 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"65120_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jcyt.2024.04.075","volume":"26","author":"A Miller","year":"2024","unstructured":"Miller, A. et al. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy 26, 1026\u20131032. https:\/\/doi.org\/10.1016\/j.jcyt.2024.04.075 (2024).","journal-title":"Cytotherapy"},{"key":"65120_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71082-y","author":"D Figueroa","year":"2026","unstructured":"Figueroa, D. et al. Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-71082-y (2026).","journal-title":"Nat. Commun."},{"key":"65120_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04178-x","volume":"74","author":"J Lutz","year":"2025","unstructured":"Lutz, J. et al. Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma. Cancer Immunol. Immunother. 74, 329. https:\/\/doi.org\/10.1007\/s00262-025-04178-x (2025).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65120-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65120-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65120-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:06:41Z","timestamp":1786162001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65120-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["65120"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-65120-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial interests: JK, JR, JL and RH are all employees of CureVac SE and may hold company shares\/stock options. RH, JK, JR and JL are inventors on the patent: RNA composition for improving cell therapy (P385WO, PCT\/EP2023\/080127).","order":1,"name":"Ethics","label":"Competings interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were conducted following protocols approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio. The care and use of animals was in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). This study was reported in accordance with ARRIVE guidelines (\n                      \n                      ).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24539"}}